Spyryx Biosciences CEO and leadership

John joined Spyryx as CEO in December 2013 with the goal of building a therapeutic development company targeting obstructive lung disease, with an initial focus on Cystic Fibrosis. This role relies heavily on his prior experience in business and corporate development for small pharmaceutical and biotechnology companies, including considerable focus on rare and orphan diseases. In addition to Spyryx, John has provided leadership to several other biopharmaceutical start-ups, including JUNCTIONRx, a company he founded to pursue orphan drug development. Previously, he spent almost four years as Vice President, Corporate Development with Synageva BioPharma (NASDAQ: GEVA), a biotechnology company focused on protein therapeutics for rare diseases, which he helped to take public via a reverse merger with Trimeris. Prior to joining Synageva, John was the Vice President, Business Development for Javelin Pharmaceuticals, a clinical and commercial stage specialty pharmaceutical company developing treatments for acute pain. Earlier in his career John held positions of increasing responsibility in licensing and business development, marketing, and sales with Eurand Pharma, Sarnoff Corporation, Amersham Pharmacia Biotech and BioWhittaker. John received his Bachelors degree in Biological Sciences from Clemson University and his Masters degree in Technology Management from the Wharton School of Business at the University of Pennsylvania.

Alistair W Wheeler Md is a Chief Medical Officer at Spyryx Biosciences. He has worked as VP:Medical Affairs at CELLDEX THERAPEUTICS, INC..